<h4>Background</h4>Anti-angiogenic therapy, particularly small-molecule inhibitors targeting the vascular endothelial growth factor receptor (VEGFR), has emerged as a promising approach for treating bone and soft tissue sarcomas. The gene discussed is KDR; the disease is soft tissue sarcoma.